Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells

  • Zhou, Wen (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University) ;
  • Wang, Jian (Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy) ;
  • Man, Wang-Ying (Department of Hematology and Oncology, Hebei United University Affiliated Hospital) ;
  • Zhang, Qing-Wei (Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University) ;
  • Xu, Wen-Gui (Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy)
  • Published : 2015.04.03
Download PDF
⟨ Previous Next ⟩

Abstract

Clinical resistance to chemotherapeutic agents is one of the major hindrances in the treatment of human cancers. EHZ2 is involved in drug resistance and is overexpressed in drug-resistant cancer cell lines. In this study, we investigated the effects of EHZ2 on cisplatin -resistance in A549/DDP and AGS/DDP cells. EHZ2 mRNA and protein were found to be significantly overexpressed in A549/DDP and AGS/DDP cells, compared to parental cells. EHZ2 siRNA successfully silenced EHZ2 mRNA and protein expression. Proliferation was inhibited and drug resistance to cisplatin was improved. Flow cytometry showed that silencing of EHZ2 arrested A549/DDP and AGS/DDP cells in the G0/G1 phase, increasing apoptosis, rh-123 fluorescence intensity and caspase-3/8 activities. Silencing of EHZ2 also significantly reduced the mRNA and protein expression levels of cyclin D1 and MDR1,while up-regulating p15, p21, p27 and miR-218 in A549/DPP cells. Furthermore, silencing of EHZ2 also significantly increased the expression level of tumor suppressor factor miR-218. We also found down-regulating EHZ2 expression increased methylation in A549/DDP and AGS/DDP cells. This study demonstrates that drug resistance can be effectively reversed in human cisplatin-resistant lung and gastric cancer cells through delivery of siRNAs targeting EHZ2.

Keywords

References

  1. Ansbro MR, Shukla S, Ambudkar SV, et al (2013). Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference. PLoS One, 8, 60334. https://doi.org/10.1371/journal.pone.0060334
  2. Avan A, Crea F, Paolicchi E, et al (2012). Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol Cancer Ther, 11, 1735-46. https://doi.org/10.1158/1535-7163.MCT-12-0037
  3. Behrens C, Solis LM, Lin H, et al (2013). EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.Clin Cancer Res, 19, 6556-65. https://doi.org/10.1158/1078-0432.CCR-12-3946
  4. Choi JH, Song YS, Yoon JS, et al (2010). Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS, 118, 196-202. https://doi.org/10.1111/j.1600-0463.2009.02579.x
  5. Fujii S, Ochiai A (2008). Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci, 99, 738-46. https://doi.org/10.1111/j.1349-7006.2008.00743.x
  6. Gadgeel SM (2013). New targets in non-small cell lung cancer.Curr Oncol Rep, 15, 411-23. https://doi.org/10.1007/s11912-013-0326-4
  7. Garapaty-Rao S, Nasveschuk C, Gagnon A, et al (2013).Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol, 20, 1329-39. https://doi.org/10.1016/j.chembiol.2013.09.013
  8. Hato SV, Khong A, de Vries IJ, et al (2014). Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res, 20, 2831-7. https://doi.org/10.1158/1078-0432.CCR-13-3141
  9. He LJ, Cai MY, Xu GL, et al (2013). Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pac J Cancer Prev, 13, 3173-8.
  10. Hensing T, Chawla A, Batra R, et al (2014). A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol, 799, 85-117. https://doi.org/10.1007/978-1-4614-8778-4_5
  11. Hu S, Yu L, Li Z, et al (2010). Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther, 10, 788-95. https://doi.org/10.4161/cbt.10.8.12913
  12. Jang WJ, Park B, Jeong GS, et al (2014). SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncol Rep, 32, 2612-8.
  13. Janjigian YY, Smit EF, Groen HJ, et al (2014). Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov, 4, 1036-45. https://doi.org/10.1158/2159-8290.CD-14-0326
  14. Li CH, To KF, Tong JH,et al(2013).Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology, 144, 1086-97. https://doi.org/10.1053/j.gastro.2013.01.058
  15. Liu T, Hou L, Huang Y(2014).EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway. Tumour Biol, 35, 7239-47. https://doi.org/10.1007/s13277-014-1950-9
  16. Peng SC, Liao CT, Peng CH, et al (2014). MicroRNAs MiR-218, MiR-125b, and Let-7g predict prognosis in patients with oral cavity squamous cell carcinoma. PLoS One, 9, 102403. https://doi.org/10.1371/journal.pone.0102403
  17. Popovic R, Martinez-Garcia E, Giannopoulou EG, et al (2014).Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.PLoS Genet, 10, 1004566. https://doi.org/10.1371/journal.pgen.1004566
  18. Powell SF, Beitinjaneh A, Tessema M, et al (2013). Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer. Clin Lung Cancer, 14, 495-501. https://doi.org/10.1016/j.cllc.2013.04.009
  19. Robson CN, Gnanapragasam V, Byrne RL, et al (1999).Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. J Endocrinol, 160, 257-66. https://doi.org/10.1677/joe.0.1600257
  20. Sherr CJ, Roberts JM(1999).CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13, 1501-12. https://doi.org/10.1101/gad.13.12.1501
  21. Shi J, Qu YP, Hou P (2014). Pathogenetic mechanisms in gastric cancer. World J Gastroenterol, 20, 13804-13819. https://doi.org/10.3748/wjg.v20.i38.13804
  22. Suzuki M, Ikeda K, Shiraishi K, et al (2014).Aberrant methylation and silencing of IRF8 expression in non-small cell lung cancer. Oncol Lett, 8, 1025-30.
  23. Sneeringer CJ, Scott MP, Kuntz KW, et al (2010).Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A, 107, 20980-5. https://doi.org/10.1073/pnas.1012525107
  24. Tamgue O, Chai CS, Hao L, et al (2013). Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. Asian Pac J Cancer Prev, 10, 5663-9.
  25. Tie J, Pan Y, Zhao L, et al (2010). MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor.PLoS Genet, 6, 1000879. https://doi.org/10.1371/journal.pgen.1000879
  26. Uesugi A, Kozaki K, Tsuruta T, et al (2011).The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res, 71, 5765-78. https://doi.org/10.1158/0008-5472.CAN-11-0368
  27. Venkataraman S, Birks DK, Balakrishnan I, et al (2013). MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem, 288, 1918-28. https://doi.org/10.1074/jbc.M112.396762
  28. Wadhwa R, Elimova E, Shiozaki H, et al (2014). Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther, 14, 367-79. https://doi.org/10.1586/14737140.2014.896207
  29. Yamaguchi H, Hung MC (2014). Regulation and Role of EZH2 in Cancer. Cancer Res Treat, 46, 209-22. https://doi.org/10.4143/crt.2014.46.3.209
  30. Zhang D, Fan D (2010). New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.Future Oncol, 6, 527-37. https://doi.org/10.2217/fon.10.21
  31. Zhang JY, Lin MT, Yi T, et al (2013). Apoptosis sensitization by Euphorbia factor L1 in ABCB1-mediated multidrug resistant K562/ADR cells. Molecules, 18, 12793-808. https://doi.org/10.3390/molecules181012793
  32. Zhang Y, Liu G, Lin C, et al (2013). Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu. Life Sci, 92, 896-902. https://doi.org/10.1016/j.lfs.2013.03.010
  33. Zheng L, Tan W, Zhang J, et al (2014). Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother, 63, 581-6. https://doi.org/10.1007/s00262-014-1541-z
  34. Zhu Y, Liu XJ, Yang P, et al (2014). Alkylglyceronephosphate synthase (AGPS) alters lipid signaling pathways and supports chemotherapy resistance of glioma and hepatic carcinoma cell lines. Asian Pac J Cancer Prev, 7, 3219-26.

Cited by

  1. Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapy vol.4, pp.12, 2015, https://doi.org/10.1002/cam4.554
  2. MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells vol.11, pp.3, 2016, https://doi.org/10.1371/journal.pone.0150026
  3. Reversing epigenetic mechanisms of drug resistance in solid tumors using targeted microRNA delivery vol.13, pp.7, 2016, https://doi.org/10.1080/17425247.2016.1178236
  4. Non-coding RNAs as regulators in epigenetics vol.37, pp.1, 2016, https://doi.org/10.3892/or.2016.5236
  5. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression vol.37, pp.5, 2016, https://doi.org/10.1007/s13277-015-4416-9
  6. Therapeutic potentials of short interfering RNAs vol.101, pp.19, 2017, https://doi.org/10.1007/s00253-017-8433-z
  7. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2 vol.127, pp.8, 2017, https://doi.org/10.1172/JCI89092
  8. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J vol.17, pp.1, 2017, https://doi.org/10.1186/s12885-017-3132-9
  9. EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe? vol.18, pp.6, 2017, https://doi.org/10.3390/ijms18061172
  10. Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells vol.185, pp.4, 2018, https://doi.org/10.1007/s12010-017-2684-0